

Application No.: 10/520,431

2

Docket No.: 57734(11259)

- V. Claims 26-38 are drawn to a method for tracking cells in vivo at any desired location.
- VI. Claims 39-48 are drawn to a composition comprising an isolated and purified cells vector encoding for a bispecific antibody and a fluorescent protein.
- VII. Claims 49-52 are drawn to a method of using cells in functional assays, wherein said assay is a T cell assay.
- VIII. Claims 49-51 and 53 are drawn to a method of using cells in functional assays, wherein said assay is an ELISA, RIA.
- IX. Claims 49-51 and 53 are drawn to a method of using cells in functional assays, wherein said assay is a cytokine assay.

Applicants respectfully request reconsideration of the Restriction Requirement as set forth. Please note, the search for Groups I and II overlap.

Applicants do not believe that any fee is due in connection with this response, however, if for any reason a fee is required, the Commissioner is hereby authorized and requested to charge Deposit Account No. 04-1105.

Dated: June 1, 2007

Respectfully submitted,

By Kathryn A. Piffat, Ph.D.
Kathryn A. Piffat, Ph.D., Esq.
Registration No.: 34,901
EDWARDS ANGELL PALMER & DODGE
LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorneys/Agents For Applicant